Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	13.13B
Revenue (ttm)	5.38B
Net Income (ttm)	718.07M
Shares Out	420.25M
EPS (ttm)	1.71
PE Ratio	18.29
Forward PE	n/a
Dividend	0.55 (1.78%)
Ex-Dividend Date	Aug 9, 2024

Volume	216,500
Average Volume	1,413,241
Open	31.50
Previous Close	31.25
Day's Range	31.15 - 31.50
52-Week Range	28.90 - 38.35
Beta	0.11
RSI	43.96
Earnings Date	Mar 28, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms. In addition, it offers contract manufacturing serv...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2023, Synmosa Biopharma's revenue was 5.14 billion, an increase of 17.19% compared to the previous year's 4.39 billion. Earnings were 594.83 million, a decrease of -25.56%.